These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

939 related articles for article (PubMed ID: 22553347)

  • 21. Bladder cancer outcome and subtype classification by gene expression.
    Blaveri E; Simko JP; Korkola JE; Brewer JL; Baehner F; Mehta K; Devries S; Koppie T; Pejavar S; Carroll P; Waldman FM
    Clin Cancer Res; 2005 Jun; 11(11):4044-55. PubMed ID: 15930339
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of cytokeratin 20 in urinary cytology of patients with bladder carcinoma.
    Klein A; Zemer R; Buchumensky V; Klaper R; Nissenkorn I
    Cancer; 1998 Jan; 82(2):349-54. PubMed ID: 9445193
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How to combine the molecular profile with the clinicopathological profile of urothelial neoplastic lesions.
    van der Kwast TH
    Scand J Urol Nephrol Suppl; 2008 Sep; (218):175-84. PubMed ID: 18815932
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray.
    Higgins JP; Kaygusuz G; Wang L; Montgomery K; Mason V; Zhu SX; Marinelli RJ; Presti JC; van de Rijn M; Brooks JD
    Am J Surg Pathol; 2007 May; 31(5):673-80. PubMed ID: 17460449
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of multidrug resistance gene expression levels with malignant potentials and influence of chemotherapy in urothelial cancers.
    Kakehi Y; Wu WJ; Kim WJ; Arao S; Fukumoto M; Yoshida O
    Int J Urol; 1995 Nov; 2(5):309-15. PubMed ID: 8749949
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [So-called "superficial" bladder tumors. Which classification in 2003? Part 2: Flat urothelial lesions].
    Sibony M; Billerey C
    Ann Pathol; 2003 Feb; 23(1):35-45. PubMed ID: 12743498
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters.
    Eltze E; Wild PJ; Wülfing C; Zwarthoff EC; Burger M; Stoehr R; Korsching E; Hartmann A
    Eur Urol; 2009 Nov; 56(5):837-45. PubMed ID: 18945538
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Altered mRNA expression of the Rb and p16 tumor suppressor genes and of CDK4 in transitional cell carcinomas of the urinary bladder associated with tumor progression.
    Quentin T; Henke C; Korabiowska M; Schlott T; Zimmerman B; Kunze E
    Anticancer Res; 2004; 24(2B):1011-23. PubMed ID: 15161057
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SOX4 expression levels in urothelial bladder carcinoma.
    Gunes S; Yegin Z; Sullu Y; Buyukalpelli R; Bagci H
    Pathol Res Pract; 2011 Jul; 207(7):423-7. PubMed ID: 21680105
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Validation of World Health Organization/International Society of Urologic Pathology 2004 classification schema for bladder urothelial carcinomas using quantitative nuclear morphometry: identification of predictive features using bootstrap method.
    Kapur U; Antic T; Venkataraman G; Durazo-Arvizu R; Quek MM; Flanigan RC; Wojcik EM
    Urology; 2007 Nov; 70(5):1028-33. PubMed ID: 18068480
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of the human mismatch repair gene hMSH2: a potential marker for urothelial malignancy.
    Leach FS; Hsieh JT; Molberg K; Saboorian MH; McConnell JD; Sagalowsky AI
    Cancer; 2000 May; 88(10):2333-41. PubMed ID: 10820356
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Invasive micropapillary urothelial carcinoma of the bladder.
    Lopez-Beltran A; Montironi R; Blanca A; Cheng L
    Hum Pathol; 2010 Aug; 41(8):1159-64. PubMed ID: 20381120
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study.
    Burger M; van der Aa MN; van Oers JM; Brinkmann A; van der Kwast TH; Steyerberg EC; Stoehr R; Kirkels WJ; Denzinger S; Wild PJ; Wieland WF; Hofstaedter F; Hartmann A; Zwarthoff EC
    Eur Urol; 2008 Oct; 54(4):835-43. PubMed ID: 18166262
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The 2004 WHO classification of bladder tumors: a summary and commentary.
    Montironi R; Lopez-Beltran A
    Int J Surg Pathol; 2005 Apr; 13(2):143-53. PubMed ID: 15864376
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alteration of the vascular endothelial growth factor and angiopoietins-1 and -2 pathways in transitional cell carcinomas of the urinary bladder associated with tumor progression.
    Quentin T; Schlott T; Korabiowska M; Käthei N; Zöller G; Glaser F; Kunze E
    Anticancer Res; 2004; 24(5A):2745-56. PubMed ID: 15517881
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma.
    Jebar AH; Hurst CD; Tomlinson DC; Johnston C; Taylor CF; Knowles MA
    Oncogene; 2005 Aug; 24(33):5218-25. PubMed ID: 15897885
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Determination of grade of urothelial carcinoma according to WHO 2004 classification].
    Kruslin B; Belicza M
    Lijec Vjesn; 2006; 128(7-8):201-6. PubMed ID: 17087133
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis.
    Hernández S; López-Knowles E; Lloreta J; Kogevinas M; Jaramillo R; Amorós A; Tardón A; García-Closas R; Serra C; Carrato A; Malats N; Real FX
    Clin Cancer Res; 2005 Aug; 11(15):5444-50. PubMed ID: 16061860
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular alterations associated with bladder cancer initiation and progression.
    Cordon-Cardo C
    Scand J Urol Nephrol Suppl; 2008 Sep; (218):154-65. PubMed ID: 18815930
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The molecular biology of bladder carcinoma].
    Moreno Sierra J; Maestro de las Casas ML; Chicharro Almarza J; Ortega Heredia MD; López García-Asenjo J; Merino Sánchez C; Blanco Jiménez E; Silmi Moyano A; Rsesel Estévez L
    Arch Esp Urol; 1997 Oct; 50(8):855-66. PubMed ID: 9463283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 47.